{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:40:29Z","timestamp":1777876829315,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Platinum-based chemotherapy is the first-line treatment choice for advanced thymic epithelial tumors (TETs), with the expected objective response rate (ORR) \u2248of 50% in thymoma and \u224820% in thymic carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the impact of relative dose intensity (RDI) on first-line treatment outcomes in TET patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective cohort referred between 2016 and 2022 at the University of Naples Federico II, Italy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Advanced TETs treated with first-line platinum chemotherapy; RDI calculated as delivered\/planned dose intensity and categorized as low (&lt;85%) or high (\u2a7e85%). Outcomes: ORR, time to next treatment (TTNT), overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty-three patients (15 thymoma, 18 carcinoma); 22 low RDI, 11 high RDI. RDI was not associated with ORR. High RDI showed longer TTNT (6.6 vs 5.0\u2009months;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.042) and numerically longer OS (86.4 vs 32.2\u2009months;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.361).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Maintaining \u2a7e85% RDI during first-line platinum chemotherapy may offer clinical benefits and warrants further validation in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251411122","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:40:27Z","timestamp":1770979227000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of relative dose intensity of first-line platinum-based chemotherapy in patients with thymic epithelial tumors: a retrospective study"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2370-2139","authenticated-orcid":false,"given":"Erica","family":"Pietroluongo","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy"},{"name":"Department of Medicine, Section of Hematology Oncology, Thoracic Oncology Program, The University of Chicago Medicine, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"De Placido","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, Napoli, Italy"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Buonaiuto","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy"},{"name":"Clinical and Translational Oncology, Scuola Superiore Meridionale, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Caltavituro","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy"},{"name":"Clinical and Translational Oncology, Scuola Superiore Meridionale, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Neola","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Ottaviano","sequence":"additional","affiliation":[{"name":"Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS- Fondazione \u201cG. Pascale,\u201d Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Tortora","sequence":"additional","affiliation":[{"name":"Regional Coordinating Center for Rare Tumors (CRCTR) of Campania Region at University Federico II, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Arpino","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovannella","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Regional Coordinating Center for Rare Tumors (CRCTR) of Campania Region at University Federico II, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"De Angelis","sequence":"additional","affiliation":[{"name":"Clinical and Translational Oncology, Scuola Superiore Meridionale, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Chiara","family":"Garassino","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology Oncology, Thoracic Oncology Program, The University of Chicago Medicine, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bianco","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Servetto","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University of Naples Federico Il, Via Sergio Pansini 5, Naples 80131, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Giuliano","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv277"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2009.03.033"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.21037\/med-23-47"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2019.11.052"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-21-290"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1800-6"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01440"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33137-4"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0166"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2014.10.006"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13822"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.06.015"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.05.023"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezw107"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251411122","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251411122","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251411122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:34:00Z","timestamp":1777588440000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251411122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":14,"alternative-id":["10.1177\/17588359251411122"],"URL":"https:\/\/doi.org\/10.1177\/17588359251411122","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"17588359251411122"}}